CJC-1295 is a synthetic peptide that is commonly used for its potential effects on growth hormone (GH) secretion. It is often marketed under names like “Thaiger Pharma CJC-1295” when produced by certain manufacturers, such as Thaiger Pharma. CJC-1295 is a modified version of the naturally occurring growth hormone-releasing hormone (GHRH), which plays a role in stimulating the release of growth hormone from the pituitary gland.
Here are some key details about CJC-1295:
CJC-1295 works by stimulating the pituitary gland to release more growth hormone, leading to an increase in IGF-1 (Insulin-like Growth Factor 1) levels. This is achieved by mimicking the action of GHRH, which promotes GH secretion in a pulsatile manner. However, CJC-1295 has been modified to have a longer half-life compared to natural GHRH, meaning it remains active in the body for longer periods, potentially making it more effective at stimulating GH release over time.
While CJC-1295 is generally considered to be safe, it may have some side effects, especially when used improperly or in excessive doses. These may include:
CJC-1295 is typically administered via subcutaneous injection. It is often used in combination with other peptides like Ipamorelin, another growth hormone secretagogue, to enhance its effectiveness.
Thaiger Pharma is a well-known manufacturer of various peptides, including CJC-1295. As with all peptide treatments, users should ensure they are purchasing from reputable sources to avoid counterfeit or unsafe products.
Please note, the use of CJC-1295 for performance enhancement or other non-medical purposes may be restricted or regulated in some regions, and its safety for long-term use is not fully established. Always consult with a healthcare professional before considering such treatments.